RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these four research peptides.
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide best documented for stimulating dermal fibroblasts to produce collagen, elastin, and other matrix proteins, while rebalancing the enzymes that break matrix down against the enzymes that inhibit them. In lab gene-expression analysis, it alters expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, with strong effects on antioxidant, DNA-repair, and ubiquitin-proteasome pathways [2]. Its best-documented human uses are topical: skin-firmness and hair-count studies, not systemic or injectable applications, which remain unapproved and largely unstudied in people.
What is GHK-Cu and how does it work?
GHK-Cu is the tripeptide glycine-histidine-lysine bound to a single copper ion — a naturally occurring molecule whose blood level falls from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. It works partly through the copper ion itself, which enables collagen/elastin cross-linking via the enzyme lysyl oxidase and provides antioxidant activity, and partly as an independent signaling molecule that shifts a broad swath of gene expression toward tissue-repair and antioxidant programs [2][4].
Is GHK-Cu peptide really anti-aging?
The evidence supports specific, measured effects rather than a general 'anti-aging' claim. A 2025 review found topical GHK-Cu increased procollagen synthesis in 70% of treated subjects, versus 50% for vitamin C and 40% for retinoic acid [1][4]. A 45-patient, 6-month hair-growth trial of a GHK-containing combination product found a statistically significant hair-count increase over placebo [3]. Those are real, cited results in specific outcomes — skin collagen and hair count — not a validated claim that GHK-Cu slows biological aging broadly; much of the wider anti-aging narrative extrapolates beyond what the controlled trials actually measured.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA that, in animal studies, inhibits the folate cycle to activate AMPK — a cellular low-fuel switch — improving glucose handling and preventing diet-induced obesity and insulin resistance in mice [11]. A 2024 study found it directly binds and activates casein kinase 2 (CK2), with effects that prevented muscle atrophy and boosted muscle glucose uptake [6]. Nearly all of this evidence is from mouse and rat studies; the only human data is an observational association between blood MOTS-c levels and cardiovascular/mortality risk in dialysis patients, not a trial of giving a person MOTS-c [7].
What are the negative side effects of MOTS-c?
There is no documented human side-effect profile for MOTS-c, because no completed human trial has tested giving a person exogenous MOTS-c — every effect and side-effect claim in circulation is extrapolated from mouse and rat studies, which is not a substitute for human safety data. What the literature does note: MOTS-c has no validated human pharmacokinetics (half-life, bioavailability, or dose-response), the rodent doses used in published studies cannot be responsibly translated to a human amount, and it is sold only as an unregulated research chemical, with purity and identity varying by supplier.
Is MOTS-c legal to buy?
MOTS-c is not an FDA-approved drug for any human use; it is sold, where available, strictly as a research chemical intended for laboratory use, not human consumption. Separately, anti-doping authorities including USADA and WADA classify MOTS-c among peptide and metabolic-modulator agents prohibited in elite sport at all times, meaning competitive athletes face sanctions for its use regardless of how it was obtained. This page describes its regulatory and research-chemical status; it does not facilitate sourcing or purchase of MOTS-c or any other compound.
What does retatrutide do?
Retatrutide is an investigational peptide that activates three receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP arms suppress appetite and boost glucose-dependent insulin secretion; the glucagon arm is intended to raise energy expenditure. In a 48-week Phase 2 trial, the 12 mg dose produced a mean -24.2% body-weight change versus -2.1% for placebo [16], and a substudy found it cut liver fat by -82.4% at 24 weeks in participants with metabolic liver disease [15]. It is not FDA-approved and remains in Phase 3 trials.
How does retatrutide work?
Retatrutide's GLP-1/GIP arms work like other incretin drugs — slowing gastric emptying and boosting insulin secretion in a glucose-dependent way, suppressing appetite. Its distinguishing feature is the third arm: calibrated glucagon-receptor activation, proposed to raise energy expenditure through fat-tissue thermogenesis and fatty-acid oxidation rather than raising blood glucose meaningfully. Cryo-EM structural work confirms it engages all three receptors with a deliberately imbalanced potency — about 8.9 times more potent than native GIP at the GIP receptor, but well under native potency at the glucagon and GLP-1 receptors [14].
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide has not been approved by the FDA or any other regulatory agency anywhere. It remains an investigational drug in Phase 3 clinical trials (the TRIUMPH program); every efficacy and safety figure on this site comes from its Phase 1 and Phase 2 data [13][16][17]. The FDA issued more than 50 warning letters to vendors selling unapproved 'research-grade' retatrutide in 2025, and material obtained outside a registered clinical trial cannot be verified for identity, purity, or sterility.
What is tirzepatide?
Tirzepatide is an FDA-approved, 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors — the first approved dual incretin agonist. It is approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity [19]. In a direct head-to-head trial, tirzepatide produced greater weight loss than semaglutide, a single-receptor comparator (-20.2% versus -13.7% at 72 weeks) [18]. In vitro assays show it engages the GIP receptor more strongly than the GLP-1 receptor, a biased signaling profile proposed to help explain its efficacy advantage over single-agonist drugs [19].
How does tirzepatide work?
By activating both GIP and GLP-1 receptors, tirzepatide boosts glucose-dependent insulin secretion from the pancreas, suppresses glucagon release, and slows gastric emptying — mechanisms that together improve blood-sugar control and reduce appetite. Because insulin release stays glucose-dependent, the mechanism carries a built-in brake against hypoglycemia when used alone. The GIP receptor arm is thought to add incrementally to the effect of GLP-1 engagement alone, though the exact contribution of each receptor to the final trial results remains an active research question [19].
What is tirzepatide used for?
Tirzepatide's FDA-approved indications are type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity [19]. In its pivotal SURMOUNT-1 obesity trial, the 15 mg dose produced -20.9% mean body-weight change versus -3.1% for placebo over 72 weeks [21], and in the SURPASS-2 diabetes trial it reduced HbA1c by up to 2.30 percentage points, outperforming semaglutide 1 mg [22].